News coverage about Apollo Endosurgery (NASDAQ:APEN) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 48.0096294501041 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Apollo Endosurgery (NASDAQ:APEN) traded up 1.38% during midday trading on Thursday, reaching $4.42. The company had a trading volume of 14,265 shares. The stock has a 50-day moving average of $5.12 and a 200 day moving average of $7.87. The firm’s market capitalization is $76.25 million. Apollo Endosurgery has a 52 week low of $2.00 and a 52 week high of $21.88.

Apollo Endosurgery (NASDAQ:APEN) last issued its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by $0.40. Apollo Endosurgery had a negative return on equity of 142.98% and a negative net margin of 81.59%. The company had revenue of $17.14 million for the quarter. On average, analysts anticipate that Apollo Endosurgery will post ($2.18) earnings per share for the current year.

A number of research analysts have recently commented on the company. Roth Capital initiated coverage on Apollo Endosurgery in a research note on Wednesday, August 2nd. They set a “buy” rating and a $10.00 price objective on the stock. Craig Hallum initiated coverage on Apollo Endosurgery in a research note on Monday, July 24th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, ValuEngine lowered Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 3rd.

COPYRIGHT VIOLATION NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/07/apollo-endosurgery-apen-given-media-impact-rating-of-0-20.html.

In other news, major shareholder Sciences L. P. Ptv II purchased 1,090,909 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average price of $5.50 per share, for a total transaction of $5,999,999.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Holdings A/S Novo sold 50,130 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $6.90, for a total value of $345,897.00. Following the completion of the sale, the insider now owns 1,334,772 shares of the company’s stock, valued at approximately $9,209,926.80. The disclosure for this sale can be found here. In the last ninety days, insiders have bought 1,277,271 shares of company stock worth $7,024,991. Insiders own 74.20% of the company’s stock.

About Apollo Endosurgery

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Receive News & Stock Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related stocks with our FREE daily email newsletter.